Terumo Corporation · TSE:4543

Terumo — FY2017 Earnings Presentation

11 slides from Terumo's earnings presentation, May 9, 2018

  1. Slide 1: FY17 Summary: Evolution of Globalization

    “FY17 Summary” y “Evolution of Globalization” Terumo Corporation President and CEO Shi ji SSato Shinjiro t May 9, 9 2018

  2. Slide 2: FY17 Summary

    FY17 Summary  Best‐ever Sales and Profit: Start Toward Achieving the Mid‐ to Long‐term Growth Strategy g  Integration of three FY16 acquisitions proceeding beyond expectations  Allll companies i made d progress, with i h Generall Hospital i l and d Blood l d Management growing i in focus areas 

  3. Slide 3: Integration of Three FY2016 Acquisitions Proceeding beyond Expectations

    Integration of Three FY2016 Acquisitions Proceeding beyond Expectations  Sequent Medical (US) Quickly, completely integrated functions from production to sales Launched easy‐to‐handle, easy to handle lower lower‐profile profile product in Europe Europe, with expectations for application to broade

  4. Slide 4: General Hospital and Blood Management growing in focus areas

    General Hospital and Blood Management growing in focus areas  General Hospital  General hospital products: Steady growth for advanced infusion system Needleless System Closed anticancer drug infusion system “Surplug AD” “Chemosafe”  Drug & Device: Pain management products “Acelio” and newly intro

  5. Slide 5: Evolution of Globalization

    Evolution of Globalization © Terumo Corporation 2018/5/9 5/11

  6. Slide 6: Globalized Revenue

    Globalized Revenue FY98 FY08 FY17 Asia, Asia Asia, Asia and Asia, etc. China etc. US China China US Japan Europe Japan US Japan Europe Europe © Terumo Corporation 2018/5/9 6/11

  7. Slide 7: Track Record of Terumo's Globalization

    Track Record of Terumo’s Globalization Evolution of Globalization  Uniform globalization + Selective regional strategy  CXO management + Leverage global talents (billion JPY) 700 Efficient Globalization  Uniform globalization under business‐led business led 600 management  Regional holdings comp

  8. Slide 8: Market, Terumo's Position, and Its Strategic Direction Vary by Region

    Market, Terumo’s Position, and Its Strategic Direction Vary by Region T Terumo’s ’ PPresence Changes in the Market High Low Direction Major Initiatives • Consolidation of users, • Approach GPO by group as Blood Vascular CV GPOs, and competitors p Expand therapeutic p business a whole TIS US • Pursue

  9. Slide 9: Pursue Regional Strategy for China and India

    Pursue Regional Strategy for China and India  Strengthen direct marketing  Transition out of distributor dependence through adopting two‐invoice system  Further utilize Hangzhou Factory for advanced and multi purposes  Begin Neuro products production. Automatize Hospital products production  Co

  10. Slide 10: Invigorate Human Resource and Organization / Bolster the brand

    Invigorate Human Resource and Organization  Boost collaboration across businesses mainly driven by CXO  Horizontal activities such as CXO CXO‐led led global meeting are in full swing Interactive, and multilateral Leverage of human resource  Appoint Chief Human Resource Officer (CHRO) and promote

  11. Slide 11: IR Contact

    IR Contact Terumo Corporation Corporate Communication (IR) Dept. E‐mail: [email protected] Among the information that Terumo discloses, the forward‐looking statements including financial projections are based upon our assumptions using information available to us at the time and are not i

Terumo — FY2017 Earnings Presentation on 6ix